{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T07:22:10Z","timestamp":1781767330601,"version":"3.54.5"},"reference-count":48,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,9]],"date-time":"2018-03-09T00:00:00Z","timestamp":1520553600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista de Gastroenterolog\u00eda de M\u00e9xico"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.rgmx.2018.02.008","type":"journal-article","created":{"date-parts":[[2018,4,17]],"date-time":"2018-04-17T23:59:36Z","timestamp":1524009576000},"page":"44-51","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["S\u00edntomas intestinales en pacientes que reciben inhibidores de bomba de protones (IBP). Resultados de una encuesta multic\u00e9ntrica en M\u00e9xico"],"prefix":"10.1016","volume":"84","author":[{"given":"M.J.","family":"Schmulson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.C.","family":"Frati-Munari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rgmx.2018.02.008_bib0245","unstructured":"American Medical Society National Historic Chemical Landmarks. Tagamet\u00ae: Discovery of histamine H2-receptor antagonist [consultado 17 Abr 2017]. Disponible en: http:\/\/www.acs.org\/content\/acs\/en\/education\/whatischemistry\/landmark\/cimetidinetagamet.htlm"},{"key":"10.1016\/j.rgmx.2018.02.008_bib0250","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1136\/gut.31.9.968","article-title":"Comparison of omeprazole and cimetidine in reflux oesophagitis: symptomatic, endoscopic and histological evaluations","volume":"31","author":"Bate","year":"1990","journal-title":"Gut"},{"key":"10.1016\/j.rgmx.2018.02.008_bib0255","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.3748\/wjg.v16.i19.2323","article-title":"Safety of the long-term use of proton pump and risk inhibitors","volume":"16","author":"Thomson","year":"2010","journal-title":"Wrld J Gastroenterol"},{"key":"10.1016\/j.rgmx.2018.02.008_bib0260","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.bpg.2013.06.001","article-title":"Safety of long-term PPI thereapy","volume":"27","author":"Reiner","year":"2013","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.rgmx.2018.02.008_bib0265","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1080\/0269905031000089378","article-title":"Association between pulmonary and digestive infections in patients receiving gastric acid-lowering medications for long-duration","volume":"17","author":"Rousseau","year":"2003","journal-title":"Brain Inj"},{"key":"10.1016\/j.rgmx.2018.02.008_bib0270","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1046\/j.1365-2036.2003.01744.x","article-title":"Gastric-acid suppressive therapy and community-acquired respiratory infections","volume":"18","author":"Laheli","year":"2003","journal-title":"Alimen Pharmacol Ther"},{"key":"10.1016\/j.rgmx.2018.02.008_bib0275","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1097\/EDE.0b013e3181b5f27d","article-title":"Acid-suppression drugs and community-acquired pneumonia","volume":"20","author":"Rodr\u00edguez","year":"2009","journal-title":"Epidemiology"},{"key":"10.1016\/j.rgmx.2018.02.008_bib0280","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1503\/cmaj.092129","article-title":"Use of acid-suppressive drugs and risk pneumonia: A systematic review and meta-analysis","volume":"183","author":"Eom","year":"2011","journal-title":"CMAJ"},{"key":"10.1016\/j.rgmx.2018.02.008_bib0285","doi-asserted-by":"crossref","first-page":"e817","DOI":"10.1542\/peds.2005-1655","article-title":"Therapy with gastric acidity inhibitors increases trhe risk of acute gastroenteritis and community-acquired pneumonia in children","volume":"117","author":"Canani","year":"2006","journal-title":"Pediatrics"},{"key":"10.1016\/j.rgmx.2018.02.008_bib0290","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/j.cgh.2007.09.010","article-title":"Use of acid-suppressing drugs and the risk of gastroenteritis","volume":"5","author":"Garc\u00eda Rodr\u00edguez","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.rgmx.2018.02.008_bib0295","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1111\/j.1572-0241.2007.01275.x","article-title":"Systematic review of the risk of enteric infection in patients taking acid suppression","volume":"102","author":"Leonard","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.rgmx.2018.02.008_bib0300","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1111\/j.1572-0241.2008.01975.x","article-title":"Gastric acid suppression by proton pump inhibitors as a risk factor for Clostridium difficile-associated diarrhea in hospitalized patients","volume":"103","author":"Aseeri","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.rgmx.2018.02.008_bib0305","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/archinternmed.2010.73","article-title":"Proton pump inhibitors and the risk for recurrent Clostridium difficile infection","volume":"170","author":"Linsky","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.rgmx.2018.02.008_bib0310","first-page":"A379","article-title":"PPIS are associated with higher C. difficile infection in critically ill patients compared to H2RA","volume":"1","author":"Eun","year":"2013","journal-title":"Un Eur Hastroenterol J"},{"key":"10.1016\/j.rgmx.2018.02.008_bib0315","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1136\/gut.35.1.23","article-title":"Duodenal bacterial overgrowth during treatment in outpatients with omeprazole","volume":"35","author":"Fried","year":"1994","journal-title":"Gut"},{"key":"10.1016\/j.rgmx.2018.02.008_bib0320","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1136\/gut.39.1.54","article-title":"Bacterial overgrowth during treatment with omeprazole compared with cimetidine: A prospective randomized double blind study","volume":"39","author":"Thorens","year":"1996","journal-title":"Gut"},{"key":"10.1016\/j.rgmx.2018.02.008_bib0325","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2036.2006.02707.x","article-title":"Review article: Proton pump inhibitors and bacterial overgrowth","volume":"23","author":"Williams","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.rgmx.2018.02.008_bib0330","doi-asserted-by":"crossref","first-page":"S142","DOI":"10.1016\/S1590-8658(09)60372-8","article-title":"Prevalence of small bowel intestinal bacterial overgrowth (SIBO) in chronic proton pump inhibitors users: A pilot case-control study","volume":"41","author":"Saettone","year":"2009","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.rgmx.2018.02.008_bib0335","first-page":"A579","article-title":"Small Intestinal bacterial overgrowth and gastrointestinal symptoms in celiac disease patients receiving proton pump inhibitors","volume":"1","author":"Zwolinska Wcislo","year":"2013","journal-title":"UEG Journal"},{"key":"10.1016\/j.rgmx.2018.02.008_bib0340","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/apt.12304","article-title":"Dysmotility and proton pump inhibitor use are independent risk factors for small intestinal bacterial and\/or fungal overgrowth","volume":"37","author":"Jacobs","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.rgmx.2018.02.008_bib0345","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.cgh.2012.12.011","article-title":"Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: A meta-analysis","volume":"11","author":"Lo","year":"2013","journal-title":"Clin Gastroentero lHepatol"},{"key":"10.1016\/j.rgmx.2018.02.008_bib0350","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.cgh.2009.12.022","article-title":"Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy","volume":"8","author":"Lombardo","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.rgmx.2018.02.008_bib0355","doi-asserted-by":"crossref","first-page":"6817","DOI":"10.3748\/wjg.v21.i22.6817","article-title":"What are the effects of proton pump inhibitors on the small intestine?","volume":"21","author":"Fujimori","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.rgmx.2018.02.008_bib0360","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12916-016-0718-z","article-title":"Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression","volume":"14","author":"Scarpignato","year":"2016","journal-title":"BMC Med"},{"key":"10.1016\/j.rgmx.2018.02.008_bib0365","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s00535-016-1227-8","article-title":"Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015","volume":"51","author":"Iwakiri","year":"2016","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.rgmx.2018.02.008_bib0370","first-page":"16","article-title":"Proton pump inhibitor prescribing and costs in a large outpatient clinic","volume":"110","author":"Hood","year":"2014","journal-title":"W V Med J"},{"key":"10.1016\/j.rgmx.2018.02.008_bib0375","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/MED.0000000000000031","article-title":"Proton pump inhibitor therapy and potential long-term harm","volume":"21","author":"Corleto","year":"2014","journal-title":"Curr Opin Endocrinol Diab Obes"},{"key":"10.1016\/j.rgmx.2018.02.008_bib0380","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.kint.2016.12.021","article-title":"Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury","volume":"91","author":"Xie","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.rgmx.2018.02.008_bib0385","doi-asserted-by":"crossref","first-page":"65","DOI":"10.5414\/CNP68065","article-title":"Proton pump inhibitors and the kidney: Critical review","volume":"68","author":"Brewster","year":"2007","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.rgmx.2018.02.008_bib0390","first-page":"S12325","article-title":"A review of the novel application and potential adverse effects of proton pump inhibitors","volume":"10","author":"Yu","year":"2017","journal-title":"Adv Ther"},{"key":"10.1016\/j.rgmx.2018.02.008_bib0395","first-page":"1038","article-title":"Proton-pump inhibitor use and the risk of first-time ischemic stroke in the general population: A nationwide population-based study","volume":"10","author":"Wang","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.rgmx.2018.02.008_bib0400","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11938-017-0115-5","article-title":"Clinical implications of emerging data on the safety of proton pump inhibitors","volume":"15","author":"Schnoll Sussman","year":"2017","journal-title":"Curr Treat Options Gastroenterol"},{"key":"10.1016\/j.rgmx.2018.02.008_bib0405","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1053\/gast.2002.32978","article-title":"The burden of selected digestive disease in the United States","volume":"122","author":"Sandler","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.rgmx.2018.02.008_bib0410","doi-asserted-by":"crossref","first-page":"113","DOI":"10.5056\/jnm.2010.16.2.113","article-title":"Irritable bowel syndrome and co-morbid gastrointestinal and extra-gastrointestinal functional syndromes","volume":"16","author":"Sperber","year":"2010","journal-title":"J Neurogastroenterol Motil"},{"key":"10.1016\/j.rgmx.2018.02.008_bib0415","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1007\/s10620-006-9306-y","article-title":"Studying the overlap between IBS and GERD: A systematic review of the literature","volume":"51","author":"Nastaskin","year":"2006","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.rgmx.2018.02.008_bib0420","doi-asserted-by":"crossref","first-page":"229","DOI":"10.4321\/S1130-01082010000400002","article-title":"Heartburn and other related symptoms are independent of body mass index in irritable bowel syndromes","volume":"102","author":"Schmulson","year":"2010","journal-title":"Rev Esp Enferm Dig"},{"key":"10.1016\/j.rgmx.2018.02.008_bib0425","doi-asserted-by":"crossref","first-page":"5787","DOI":"10.3748\/wjg.v19.i35.5787","article-title":"Overlap of functional heartburn and gastroesophageal reflux disease with irritable bowel syndrome","volume":"19","author":"De Bortoli","year":"2013","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.rgmx.2018.02.008_bib0430","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.12082","article-title":"Associations between medication use and functional gastrointestinal disorders: A population-based study","volume":"25","author":"Choung","year":"2013","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.rgmx.2018.02.008_bib0435","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1111\/j.1572-0241.2008.01992.x","article-title":"Bacterial overgrowth and irritable bowel syndrome: Unifying hypothesis or a spurious consequence of proton pump inhibitors?","volume":"103","author":"Spiegel","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.rgmx.2018.02.008_bib0440","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/j.1365-2362.2010.02419.x","article-title":"Effect of long-term PPI treatment on producing bowel symptoms and SIBO","volume":"41","author":"Compare","year":"2010","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.rgmx.2018.02.008_bib0445","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S1590-8658(09)60053-0","article-title":"Proton pump inhibitors long-term therapy impairs oro-cecal transit time and predisposes to small intestinal bacterial overgrowth","volume":"41","author":"Pica","year":"2009","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.rgmx.2018.02.008_bib0450","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.dld.2013.08.128","article-title":"Use of proton pump inhibitors and subsequent risk of celiac disease","volume":"46","author":"Lebowohl","year":"2014","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.rgmx.2018.02.008_bib0455","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.cgh.2009.06.031","article-title":"Small intestinal bacterial overgrowth in irritable bowel syndrome: A systematic review and meta-analysis","volume":"7","author":"Ford","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.rgmx.2018.02.008_bib0460","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2982.2012.01898.x","article-title":"Clustering and stability of functional lower gastrointestinal symptom after enteric infection","volume":"24","author":"Thabane","year":"2012","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.rgmx.2018.02.008_bib0465","first-page":"96","article-title":"Microbiota, gastrointestinal infections, low grade inflammation, and antibiotic therapy in irritable bowel syndrome (IBS): An evidence-based review","volume":"79","author":"Schmulson","year":"2014","journal-title":"Rev Gastroenterol Mex"},{"key":"10.1016\/j.rgmx.2018.02.008_bib0470","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/apt.13568","article-title":"A comparison of the gut microbiome between long-term users and non-users of proton pump inhibitors","volume":"43","author":"Clooney","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.rgmx.2018.02.008_bib0475","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.jamda.2016.04.020","article-title":"Effect of a proton pump inhibitor deprescribing guideline on drug usage and costs in long-term care","volume":"17","author":"Thompson","year":"2016","journal-title":"J Am Med Dir Assoc"},{"key":"10.1016\/j.rgmx.2018.02.008_bib0480","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/ajg.2017.46","article-title":"Hydrogen and methane-based breath testing in gastrointestinal disorders: The North American Consensus","volume":"112","author":"Rezaie","year":"2017","journal-title":"Am J Gastroenterol"}],"container-title":["Revista de Gastroenterolog\u00eda de M\u00e9xico"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0375090618300624?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0375090618300624?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T07:07:13Z","timestamp":1551337633000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0375090618300624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0375090618300624"],"URL":"https:\/\/doi.org\/10.1016\/j.rgmx.2018.02.008","relation":{},"ISSN":["0375-0906"],"issn-type":[{"value":"0375-0906","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"S\u00edntomas intestinales en pacientes que reciben inhibidores de bomba de protones (IBP). Resultados de una encuesta multic\u00e9ntrica en M\u00e9xico","name":"articletitle","label":"Article Title"},{"value":"Revista de Gastroenterolog\u00eda de M\u00e9xico","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rgmx.2018.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Asociaci\u00f3n Mexicana de Gastroenterolog\u00eda. Published by Masson Doyma M\u00e9xico S.A.","name":"copyright","label":"Copyright"}]}}